Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus IOPAMIDOL 200 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus IOPAMIDOL 200 IN PLASTIC CONTAINER.
HYPAQUE SODIUM 20% vs IOPAMIDOL-200 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hypaque sodium is an ionic monomeric iodinated contrast medium that absorbs X-rays due to its iodine content, providing radiographic contrast. It increases the density of vascular structures and organ parenchyma, allowing visualization during imaging procedures.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing vascular and tissue contrast during imaging procedures.
Intravenous: 30-60 mL (6-12 g iodine) administered as a bolus or infusion for excretory urography; may be repeated up to a total of 125 mL (25 g iodine). Intra-arterial: Variable based on procedure, typically 8-30 mL for selective angiography.
Intravascular administration: 1-2 mL/kg (200 mg I/mL) intravenously, up to a maximum of 150 mL per diagnostic procedure. Intraarterial administration: varies by procedure; typical 5-60 mL per injection.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment.
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function; prolonged in renal impairment.
Renal: >95% unchanged via glomerular filtration within 24 hours; <5% biliary/fecal.
Primarily renal (99% unchanged in urine within 24 hours). Biliary/fecal excretion <1%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent